Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...

Pole Star Global, a world leader in maritime intelligence and regulatory compliance solutions, today announced the launch of the Maritime Transparency Index (MTI) -- a machine learning-powered risk ...

Mainz Biomed signed a Memorandum of Understanding (“MOU”) with OncoVanguard8, a distributor of oncological innovations. The collaboration aims to introduce ColoAlert ® to South America, starting with ...